perphenazine ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2113 58-39-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • perphenazine
  • perfenazine
  • perfenil
  • perphenan
  • perphenazin
  • thilatazin
  • tranquisan
  • perphanzine
An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
  • Molecular weight: 403.97
  • Formula: C21H26ClN3OS
  • CLOGP: 4.01
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 29.95
  • ALOGS: -4.23
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
7 mg P
10 mg P
16 mg R

ADMET properties:

PropertyValueReference
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.99 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 40 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 18 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 27 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.07 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 9.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Feb. 27, 1957 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Blood magnesium increased 73.93 24.73 19 2518 2861 50599726
Pleural thickening 70.90 24.73 18 2519 2581 50600006
Pleural fibrosis 70.89 24.73 19 2518 3365 50599222
Presbyacusis 69.73 24.73 18 2519 2758 50599829
Tardive dyskinesia 68.64 24.73 22 2515 7257 50595330
Sopor 63.21 24.73 27 2510 19852 50582735
Deafness neurosensory 61.11 24.73 18 2519 4483 50598104
Epigastric discomfort 56.40 24.73 18 2519 5852 50596735
Mitochondrial encephalomyopathy 52.37 24.73 7 2530 22 50602565
Cyst 46.98 24.73 19 2518 12168 50590419
Drug abuse 46.91 24.73 32 2505 59814 50542773
Ileus paralytic 45.51 24.73 14 2523 4036 50598551
Blood potassium increased 41.55 24.73 19 2518 16379 50586208
Osteopenia 40.88 24.73 19 2518 16999 50585588
Deformity 36.28 24.73 14 2523 7926 50594661
Moaning 34.68 24.73 8 2529 766 50601821
Skin lesion 32.79 24.73 19 2518 26708 50575879
Neuroleptic malignant syndrome 31.71 24.73 14 2523 11116 50591471
Bone cyst 31.48 24.73 9 2528 2015 50600572
Hyperprolactinaemia 31.01 24.73 10 2527 3355 50599232
Osteosclerosis 30.72 24.73 10 2527 3457 50599130
Metabolic syndrome 30.28 24.73 8 2529 1339 50601248
Muscle rigidity 30.07 24.73 13 2524 9816 50592771
Intentional self-injury 29.87 24.73 17 2520 23095 50579492
Dry eye 29.58 24.73 19 2518 32076 50570511
Bradykinesia 29.45 24.73 10 2527 3933 50598654
Sports injury 27.17 24.73 4 2533 29 50602558
Blood glucose 27.05 24.73 4 2533 30 50602557
Onychophagia 25.35 24.73 4 2533 48 50602539

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Therapeutic product effect variable 325.64 51.90 63 2051 1814 29570599
Antipsychotic drug level below therapeutic 322.47 51.90 63 2051 1911 29570502
Akathisia 320.68 51.90 78 2036 6664 29565749
Obsessive-compulsive disorder 312.52 51.90 71 2043 4505 29567908
Disinhibition 305.00 51.90 63 2051 2544 29569869
Euphoric mood 276.87 51.90 65 2049 4760 29567653
Increased appetite 252.05 51.90 63 2051 6001 29566412
Suicide attempt 151.78 51.90 65 2049 34045 29538368
Therapeutic product effect incomplete 139.76 51.90 64 2050 39241 29533172
Dyslipidaemia 128.30 51.90 37 2077 6024 29566389
Toxicity to various agents 122.90 51.90 100 2014 173561 29398852
Leukopenia 121.95 51.90 65 2049 55138 29517275
Weight increased 109.67 51.90 68 2046 76599 29495814
Leukaemia 106.84 51.90 29 2085 3781 29568632
Obesity 106.59 51.90 36 2078 9827 29562586
Prescribed overdose 91.08 51.90 31 2083 8652 29563761
Neuroleptic malignant syndrome 56.28 51.90 26 2088 16122 29556291
Schizoaffective disorder 53.62 51.90 13 2101 1079 29571334

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Akathisia 98.09 25.62 33 3532 11477 64483690
Blood magnesium increased 69.90 25.62 19 3546 3212 64491955
Antipsychotic drug level below therapeutic 69.37 25.62 15 3550 970 64494197
Presbyacusis 69.31 25.62 18 3547 2557 64492610
Pleural thickening 68.40 25.62 18 3547 2692 64492475
Neuroleptic malignant syndrome 66.94 25.62 31 3534 24965 64470202
Tardive dyskinesia 65.30 25.62 23 3542 9155 64486012
Completed suicide 64.01 25.62 70 3495 224344 64270823
Therapeutic product effect variable 61.72 25.62 15 3550 1629 64493538
Pleural fibrosis 61.24 25.62 18 3547 4032 64491135
Disinhibition 57.09 25.62 15 3550 2228 64492939
Obsessive-compulsive disorder 53.96 25.62 17 3548 4801 64490366
Toxicity to various agents 53.96 25.62 82 3483 363431 64131736
Deafness neurosensory 53.20 25.62 18 3547 6356 64488811
Sopor 53.20 25.62 28 3537 29633 64465534
Epigastric discomfort 52.03 25.62 18 3547 6793 64488374
Mitochondrial encephalomyopathy 50.57 25.62 7 3558 27 64495140
Euphoric mood 48.73 25.62 17 3548 6574 64488593
Cyst 45.42 25.62 19 3546 12008 64483159
Intentional self-injury 45.32 25.62 25 3540 29019 64466148
Dyslipidaemia 43.13 25.62 17 3548 9225 64485942
Hyperprolactinaemia 40.00 25.62 13 3552 4052 64491115
Osteopenia 37.66 25.62 18 3547 15522 64479645
Ileus paralytic 37.60 25.62 15 3550 8400 64486767
Schizoaffective disorder 37.46 25.62 10 3555 1577 64493590
Obesity 35.69 25.62 19 3546 20543 64474624
Increased appetite 34.89 25.62 15 3550 10131 64485036
Deformity 34.44 25.62 13 3552 6284 64488883
Bradyphrenia 32.65 25.62 14 3551 9392 64485775
Drug abuse 32.05 25.62 38 3527 132336 64362831
Moaning 31.74 25.62 8 3557 1008 64494159
Blood potassium increased 31.55 25.62 19 3546 25961 64469206
Muscle rigidity 29.92 25.62 16 3549 17457 64477710
Bone cyst 29.88 25.62 9 3556 2188 64492979
Dry eye 29.61 25.62 19 3546 29000 64466167
Enuresis 27.77 25.62 9 3556 2781 64492386
Atrioventricular block 26.35 25.62 13 3552 12002 64483165
Osteosclerosis 25.80 25.62 9 3556 3477 64491690
Blood glucose 25.72 25.62 4 3561 39 64495128

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N05AB03 NERVOUS SYSTEM
PSYCHOLEPTICS
ANTIPSYCHOTICS
Phenothiazines with piperazine structure
FDA CS M0016525 Phenothiazines
MeSH PA D014150 Antipsychotic Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D002492 Central Nervous System Depressants
MeSH PA D015259 Dopamine Agents
MeSH PA D018492 Dopamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D011619 Psychotropic Drugs
MeSH PA D014149 Tranquilizing Agents
CHEBI has role CHEBI:37930 phenothiazine antipsychotic drugs
CHEBI has role CHEBI:48561 dopaminergic antagonists
CHEBI has role CHEBI:50919 antiemetico
FDA EPC N0000175746 Phenothiazine

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Nausea and vomiting indication 16932000
Schizophrenia indication 58214004 DOID:5419
Mixed anxiety and depressive disorder indication 231504006
Suicidal thoughts contraindication 6471006
Alcoholism contraindication 7200002
Organophosphate poisoning contraindication 8260003
Weight gain finding contraindication 8943002
Sinus tachycardia contraindication 11092001
Neuroleptic malignant syndrome contraindication 15244003 DOID:14464
Senile dementia contraindication 15662003
Chronic disease of respiratory system contraindication 17097001
Myocardial infarction contraindication 22298006 DOID:5844
Glaucoma contraindication 23986001 DOID:1686
Orthostatic hypotension contraindication 28651003
Torsades de pointes contraindication 31722008
Parkinsonism contraindication 32798002
Hyperthyroidism contraindication 34486009 DOID:7998
Conduction disorder of the heart contraindication 44808001
Chronic heart failure contraindication 48447003
Bradycardia contraindication 48867003
Paralytic ileus contraindication 55525008 DOID:8442
Extrapyramidal disease contraindication 76349003
Hyperglycemia contraindication 80394007 DOID:4195
Chronic idiopathic constipation contraindication 82934008
Open-angle glaucoma contraindication 84494001 DOID:1067
Epilepsy contraindication 84757009 DOID:1826
Leukopenia contraindication 84828003 DOID:615
Stupor contraindication 89458003
Tardive dyskinesia contraindication 102449007
Prolonged QT interval contraindication 111975006
Acute disease of cardiovascular system contraindication 128487001
Bipolar affective disorder, current episode manic contraindication 191618007
Angina pectoris contraindication 194828000
Disease of liver contraindication 235856003 DOID:409
Metabolic syndrome X contraindication 237602007 DOID:14221
Hyperprolactinemia contraindication 237662005 DOID:12700
Benign prostatic hyperplasia contraindication 266569009
Retention of urine contraindication 267064002
Syncope contraindication 271594007
Anemia contraindication 271737000 DOID:2355
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Coma contraindication 371632003
At risk for aspiration contraindication 371736008
Angle-closure glaucoma contraindication 392291006 DOID:13550
Visual impairment contraindication 397540003
Breastfeeding (mother) contraindication 413712001
Myocardial ischemia contraindication 414795007 DOID:3393
Obesity contraindication 414916001 DOID:9970
Myocardial infarction in recovery phase contraindication 418044006
Congenital long QT syndrome contraindication 442917000
Carcinoma of female breast contraindication 447782002




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.21 Basic
pKa2 4.21 Basic
pKa3 2.21 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR ANTAGONIST Ki 9.32 WOMBAT-PK CHEMBL
Alpha-2A adrenergic receptor GPCR Ki 6.19 WOMBAT-PK
Potassium voltage-gated channel subfamily H member 2 Ion channel Ki 5.46 DRUG MATRIX
5-hydroxytryptamine receptor 1A GPCR Ki 6.07 WOMBAT-PK
5-hydroxytryptamine receptor 2A GPCR Ki 8.25 WOMBAT-PK
5-hydroxytryptamine receptor 2C GPCR Ki 6.88 WOMBAT-PK
5-hydroxytryptamine receptor 6 GPCR Ki 7.55 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR Ki 7.64 WOMBAT-PK
Alpha-1A adrenergic receptor GPCR Ki 8 WOMBAT-PK
Alpha-2B adrenergic receptor GPCR Ki 6.98 WOMBAT-PK
D(3) dopamine receptor GPCR Ki 9.52 WOMBAT-PK
Histamine H1 receptor GPCR Ki 8.09 WOMBAT-PK
Muscarinic acetylcholine receptor M3 GPCR Ki 5.73 PDSP
Aldehyde oxidase Enzyme IC50 7.48 WOMBAT-PK
Alpha-2C adrenergic receptor GPCR Ki 7.07 WOMBAT-PK
D(4) dopamine receptor GPCR Ki 7.59 WOMBAT-PK
5-hydroxytryptamine receptor 7 GPCR ANTAGONIST Ki 7.60 IUPHAR
5-hydroxytryptamine receptor 6 GPCR ANTAGONIST Ki 7.80 IUPHAR
Pleiotropic ABC efflux transporter of multiple drugs Transporter IC50 5.85 CHEMBL

External reference:

IDSource
4017939 VUID
N0000146289 NUI
D00503 KEGG_DRUG
4017939 VANDF
C0031184 UMLSCUI
CHEBI:8028 CHEBI
CHEMBL567 ChEMBL_ID
D010546 MESH_DESCRIPTOR_UI
DB00850 DRUGBANK_ID
4748 PUBCHEM_CID
209 IUPHAR_LIGAND_ID
637 INN_ID
FTA7XXY4EZ UNII
8076 RXNORM
2271 MMSL
5261 MMSL
d00855 MMSL
001477 NDDF
387229007 SNOMEDCT_US
41147003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0042 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0042 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0073 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0073 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0330 TABLET, FILM COATED 2 mg ORAL ANDA 20 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0330 TABLET, FILM COATED 2 mg ORAL ANDA 20 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0442 TABLET, FILM COATED 2 mg ORAL ANDA 20 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0442 TABLET, FILM COATED 2 mg ORAL ANDA 20 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0574 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine and Amitriptyline Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 2 0378-0574 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0378-5350 TABLET, FILM COATED 2 mg ORAL ANDA 18 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0378-5351 TABLET, FILM COATED 4 mg ORAL ANDA 18 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0378-5352 TABLET, FILM COATED 8 mg ORAL ANDA 18 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0378-5353 TABLET, FILM COATED 16 mg ORAL ANDA 18 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4101 TABLET, FILM COATED 2 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4102 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4103 TABLET, FILM COATED 8 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0591-4104 TABLET, FILM COATED 16 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0603-5060 TABLET, FILM COATED 2 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0603-5061 TABLET, FILM COATED 4 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0603-5062 TABLET, FILM COATED 8 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0603-5063 TABLET, FILM COATED 16 mg ORAL ANDA 19 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8046 TABLET, FILM COATED 2 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8046 TABLET, FILM COATED 2 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8047 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8047 TABLET, FILM COATED 4 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8048 TABLET, FILM COATED 8 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8048 TABLET, FILM COATED 8 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8049 TABLET, FILM COATED 16 mg ORAL ANDA 20 sections
Perphenazine HUMAN PRESCRIPTION DRUG LABEL 1 0781-8049 TABLET, FILM COATED 16 mg ORAL ANDA 20 sections